Cell Design Institute, Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Center for Cellular Construction, University of California San Francisco, San Francisco, CA, USA.
Science. 2021 Mar 12;371(6534):1166-1171. doi: 10.1126/science.abc1855. Epub 2021 Feb 25.
Overexpressed tumor-associated antigens [for example, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)] are attractive targets for therapeutic T cells, but toxic "off-tumor" cross-reaction with normal tissues that express low levels of target antigen can occur with chimeric antigen receptor (CAR)-T cells. Inspired by natural ultrasensitive response circuits, we engineered a two-step positive-feedback circuit that allows human cytotoxic T cells to discriminate targets on the basis of a sigmoidal antigen-density threshold. In this circuit, a low-affinity synthetic Notch receptor for HER2 controls the expression of a high-affinity CAR for HER2. Increasing HER2 density thus has cooperative effects on T cells-it increases both CAR expression and activation-leading to a sigmoidal response. T cells with this circuit show sharp discrimination between target cells expressing normal amounts of HER2 and cancer cells expressing 100 times as much HER2, both in vitro and in vivo.
过表达的肿瘤相关抗原(例如表皮生长因子受体(EGFR)和人表皮生长因子受体 2(HER2))是治疗性 T 细胞的有吸引力的靶标,但嵌合抗原受体(CAR)-T 细胞可能与低水平表达靶抗原的正常组织发生有毒的“脱靶”交叉反应。受天然超敏反应回路的启发,我们设计了一个两步正反馈回路,允许人细胞毒性 T 细胞根据抗原密度的 S 形阈值来区分靶标。在该回路中,用于 HER2 的低亲和力合成 Notch 受体控制用于 HER2 的高亲和力 CAR 的表达。因此,HER2 密度的增加对 T 细胞具有协同作用——它既增加了 CAR 的表达又增加了其激活——导致 S 形反应。该回路中的 T 细胞在体外和体内均能在表达正常量 HER2 的靶细胞与表达 100 倍 HER2 的癌细胞之间进行锐利区分。
Zhonghua Bing Li Xue Za Zhi. 2017-10-8
J Immunother Cancer. 2025-8-25
Front Immunol. 2025-7-17
Nat Chem Biol. 2025-8-1
Signal Transduct Target Ther. 2025-7-9
Front Immunol. 2025-4-16
J Immunother Cancer. 2025-4-29
Nat Chem Biol. 2025-3-28
Nat Biotechnol. 2020-3-23
Nat Chem Biol. 2019-3-25
N Engl J Med. 2018-12-1
Oncoimmunology. 2018-8-1
Cell Death Dis. 2018-2-15
N Engl J Med. 2018-2-1
N Engl J Med. 2017-12-28
Nat Rev Clin Oncol. 2017-8-31